Early-phase investigations in relapsed PCNSL/SCNSL
| Agent/study . | Design . | Response rate . | PFS . | Comments . |
|---|---|---|---|---|
| Ibrutinib NCT02315326 | MSKCC phase 1 in relapsed PCNSL/SCNSL | 75% | 4.6 mo. | One case pulmonary aspergillosis; ibrutinib resistance with CARD11 mutation. |
| Ibrutinib NCT02542514 | French LOC network phase 2 in relapsed PCNSL and IOL | 56% | One case pulmonary aspergillosis; final analysis pending | |
| DA-TEDDi-R with ibrutinib monotherapy NCT02203526 | NCI phase 1 in newly diagnosed and relapsed PCNSL | 94% ibrutinib 86% CR rate with TEDDiR | 39% rate of invasive aspergillosis in lungs and brain; 28% treatment-related mortality. | |
| Temsirolimus NCT00942747 | Phase 1/2 in relapsed PCNSL | 54% | 2.1 mo. | 13.5% treatment-related mortality (pneumonia) |
| Nivolumab NCT02857426 | Phase 2 in recurrent, PCNSL and primary testicular NHL | In progress | ||
| Lenalidomide/rituximab NCT01542918 | UCSF phase 1 in relapsed PCNSL/SCNSL | 64% | 6 mo. | Independent, retrospective cohort: 12-fold increase in response duration in CR2-4 with lenalidomide maintenance compared with CR1 in relapsed PCNSL/SCNSL |
| Lenalidomide/rituximab NCT01956695 | French LOC network phase 2 in relapsed PCNSL/PVRL | 63% | 8.9 mo. | Final analysis pending |
| Pomalidomide/dex NCT01722305 | Phase 1 in relapsed PCNSL or newly diagnosed or relapsed IOL | In Progress |
| Agent/study . | Design . | Response rate . | PFS . | Comments . |
|---|---|---|---|---|
| Ibrutinib NCT02315326 | MSKCC phase 1 in relapsed PCNSL/SCNSL | 75% | 4.6 mo. | One case pulmonary aspergillosis; ibrutinib resistance with CARD11 mutation. |
| Ibrutinib NCT02542514 | French LOC network phase 2 in relapsed PCNSL and IOL | 56% | One case pulmonary aspergillosis; final analysis pending | |
| DA-TEDDi-R with ibrutinib monotherapy NCT02203526 | NCI phase 1 in newly diagnosed and relapsed PCNSL | 94% ibrutinib 86% CR rate with TEDDiR | 39% rate of invasive aspergillosis in lungs and brain; 28% treatment-related mortality. | |
| Temsirolimus NCT00942747 | Phase 1/2 in relapsed PCNSL | 54% | 2.1 mo. | 13.5% treatment-related mortality (pneumonia) |
| Nivolumab NCT02857426 | Phase 2 in recurrent, PCNSL and primary testicular NHL | In progress | ||
| Lenalidomide/rituximab NCT01542918 | UCSF phase 1 in relapsed PCNSL/SCNSL | 64% | 6 mo. | Independent, retrospective cohort: 12-fold increase in response duration in CR2-4 with lenalidomide maintenance compared with CR1 in relapsed PCNSL/SCNSL |
| Lenalidomide/rituximab NCT01956695 | French LOC network phase 2 in relapsed PCNSL/PVRL | 63% | 8.9 mo. | Final analysis pending |
| Pomalidomide/dex NCT01722305 | Phase 1 in relapsed PCNSL or newly diagnosed or relapsed IOL | In Progress |
IOL, intraocular lymphoma; NHL, non-Hodgkin lymphoma; PVRL, primary vitreoretinal lymphoma.